Abstract
Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.
Original language | English (US) |
---|---|
Pages (from-to) | 139-148 |
Number of pages | 10 |
Journal | Future Cardiology |
Volume | 12 |
Issue number | 2 |
DOIs | |
State | Published - Mar 2016 |
Keywords
- LDL
- PCSK9 inhibitors
- alirocumab
- evolocumab
- monoclonal antibodies
- statin intolerance
ASJC Scopus subject areas
- Molecular Medicine
- Cardiology and Cardiovascular Medicine